{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:32:52Z","timestamp":1792056772285,"version":"4.4.0"},"reference-count":94,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T00:00:00Z","timestamp":1698192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Biological medications for inflammatory bowel disease (IBD) account for a significant burden on provincial budgets. In an effort to curb these rising costs, nationwide switching to biosimilars is expected to be complete in Canada before the end of 2023. Biosimilar products do not require the same rigor for licensing as the originator and therefore there has been appropriate scepticism as to how biosimilars will perform in real-world practice.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We have performed a systematic review including real-world observational studies of adult patients with IBD. The primary outcome was clinical effectiveness and\/or safety in patients who had switched from originator to biosimilar anti-TNF. Secondary outcomes included loss of response (LOR), treatment persistence or cessation and immunogenicity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We included 43 studies (7,462 patients [70 percent Crohn\u2019s disease: 30 percent ulcerative colitis]; 32 infliximab studies, and 11 adalimumab studies). For infliximab, 75 percent patients were in clinical remission at the time of switch and 75 percent maintained clinical remission beyond 12 months, compared to 78 percent of patients who continued originator. For adalimumab, 86 percent patients were in remission at the time of switch with 82 percent maintaining remission at 6 months follow-up. Injection site pain was higher in patients who switched to a citrate containing adalimumab biosimilar, compared with those who continued originator. All other outcomes (LOR, treatment cessation or persistence and serious adverse events) were similar to patients who continued originator (in comparator cohorts or the available literature).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Whilst ongoing vigilance is required, these data are reassuring to both patients and clinicians and will significantly help to reduce health-care costs across Canada.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jcag\/gwad027","type":"journal-article","created":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T18:48:21Z","timestamp":1698259701000},"page":"30-45","source":"Crossref","is-referenced-by-count":9,"title":["An Update on Anti-TNF Biosimilar Switching\u2014Real-World Clinical Effectiveness and Safety"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8283-6148","authenticated-orcid":false,"given":"Susanna","family":"Meade","sequence":"first","affiliation":[{"name":"University of British Columbia , Vancouver, BC V6T 1Z4 , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Squirell","sequence":"additional","affiliation":[{"name":"University of British Columbia , Vancouver, BC V6T 1Z4 , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9961-0372","authenticated-orcid":false,"given":"Thomas Tam","family":"Hoang","sequence":"additional","affiliation":[{"name":"University of British Columbia , Vancouver, BC V6T 1Z4 , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Chow","sequence":"additional","affiliation":[{"name":"BioPro Biologics Pharmacy , 845 West Broadway, Vancouver, BC V5Z1J9 , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Rosenfeld","sequence":"additional","affiliation":[{"name":"University of British Columbia , Vancouver, BC V6T 1Z4 , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,10,25]]},"reference":[{"key":"2024020222264962400_CIT0001","author":"Government of Canada","year":"2022"},{"key":"2024020222264962400_CIT0002","first-page":"3191","article-title":"\u201cBiosimilars: The Science of Extrapolation.\u201d","volume-title":"Blood","author":"Weise","year":"2014"},{"key":"2024020222264962400_CIT0003"},{"key":"2024020222264962400_CIT0004","first-page":"1287","article-title":"\u201cClinical Outcomes Following a Switch from Remicade R to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study.\u201d","volume-title":"Journal of Crohn\u2019s & Colitis","author":"Smits","year":"2016"},{"key":"2024020222264962400_CIT0005","first-page":"3117","article-title":"\u201cLong-Term Clinical Outcomes After Switching from Remicade R to Biosimilar CT-P13 in Inflammatory Bowel Disease.\u201d","volume-title":"Digestive Diseases and Sciences","author":"Smits","year":"2017"},{"key":"2024020222264962400_CIT0006","first-page":"172","article-title":"\u201cDrug Survival and Immunogenicity After Switching From Remicade to Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: Two-year Follow-up of a Prospective Observational Cohort Study.\u201d","volume-title":"Inflammatory Bowel Diseases","author":"Smits","year":"2019"},{"key":"2024020222264962400_CIT0007","first-page":"568","article-title":"\u201cThe PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy.\u201d","volume-title":"Inflammatory Bowel Diseases","author":"Armuzzi","year":"2019"},{"key":"2024020222264962400_CIT0008","first-page":"1756284818801244","article-title":"\u201cSwitching From Originator Infliximab to the Biosimilar CT-P13 in 313 Patients with Inflammatory Bowel Disease.\u201d","volume-title":"Therapeutic Advances in Gastroenterology","author":"Bergqvist","year":"2018"},{"key":"2024020222264962400_CIT0009","first-page":"410","article-title":"\u201cProcess and Clinical Outcomes of a Biosimilar Adoption Program with Infliximab-Dyyb.\u201d","volume-title":"Journal of Managed Care & Specialty Pharmacy","author":"Bhat","year":"2020"},{"key":"2024020222264962400_CIT0010","first-page":"699","article-title":"\u201cShort Article: Switching to a Infliximab Biosimilar: Short-Term Results of Clinical Monitoring in Patients with Inflammatory Bowel Disease.\u201d","volume-title":"European Journal of Gastroenterology & Hepatology","author":"Binkhorst","year":"2018"},{"key":"2024020222264962400_CIT0011","first-page":"297","article-title":"\u201cSwitching from Remicade R to Remsima R is well Tolerated and Feasible: A Prospective, Open-label Study.\u201d","volume-title":"Journal of Crohn\u2019s & Colitis","author":"Buer","year":"2017"},{"key":"2024020222264962400_CIT0012","first-page":"1380","article-title":"\u201cEffectiveness and Safety of the Switch from Remicade\u00ae to CT-P13 in Patients with Inflammatory Bowel Disease.\u201d","volume-title":"J Crohns Colitis","author":"Chaparro","year":"2019"},{"key":"2024020222264962400_CIT0013","first-page":"1756284819858052","article-title":"\u201cLong-Term Follow up After Switching from Original Infliximab to an Infliximab Biosimilar: Real-World Data.\u201d","volume-title":"Therapeutic Advances in Gastroenterology","author":"Guerra Veloz","year":"2019"},{"key":"2024020222264962400_CIT0014","first-page":"564","article-title":"\u201cSwitching From Reference Infliximab to CT-P13 in Patients with Inflammatory Bowel Disease: Results of a Multicenter Study After 12 Months.\u201d","volume-title":"Revista espanola de enfermedades digestivas: organo oficial de la Sociedad Espanola de Patologia Digestiva","author":"Guerra Veloz","year":"2018"},{"key":"2024020222264962400_CIT0015","first-page":"1117","article-title":"\u201cSwitching from Infliximab Originator to a First Biosimilar is Safe and Effective. Results of a Case-Control Study with Drug Levels and Antibodies Evaluation.\u201d","volume-title":"Digestive and Liver Disease","author":"Guiotto","year":"2019"},{"key":"2024020222264962400_CIT0016","first-page":"128","article-title":"\u201cSwitching Australian Patients with Moderate to Severe Inflammatory Bowel Disease from Originator to Biosimilar Infliximab: A Multicentre, Parallel Cohort Study.\u201d","volume-title":"The Medical Journal of Australia","author":"Haifer","year":"2021"},{"key":"2024020222264962400_CIT0017","first-page":"495","article-title":"\u201cMultiple Switches From the Originator Infliximab to Biosimilars Is Effective and Safe in Inflammatory Bowel Disease: A Prospective Multicenter Cohort Study.\u201d","volume-title":"Inflammatory Bowel Diseases","author":"Hanzel","year":"2022"},{"key":"2024020222264962400_CIT0018","first-page":"1435","article-title":"\u201cSwitching From Originator Infliximab to Biosimilar Versus Continuing on Originator in Inflammatory Bowel disease: Results from the Observational Project NORTH Study.\u201d","volume-title":"Scandinavian Journal of Gastroenterology","author":"Hellstr\u00f6m","year":"2022"},{"key":"2024020222264962400_CIT0019","first-page":"395","article-title":"\u201cEffectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Study.\u201d","volume-title":"BioDrugs","author":"Ho","year":"2020"},{"key":"2024020222264962400_CIT0020","first-page":"692","article-title":"\u201cSwitching from Originator to Biosimilar Infliximab - Real World Data of a Prospective 18 Months Follow-Up of a Single-Centre IBD Population.\u201d","volume-title":"Scandinavian Journal of Gastroenterology","author":"Hoivik","year":"2018"},{"key":"2024020222264962400_CIT0021","first-page":"91","article-title":"\u201cInfliximab Biosimilar (RemsimaTM) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre.\u201d","volume-title":"Digestive Diseases","author":"Kolar","year":"2017"},{"key":"2024020222264962400_CIT0022","first-page":"222","article-title":"\u201cLong-Term Effectiveness and Pharmacokinetics of the Infliximab Biosimilar CT-P13 After Switching from the Originator During the Treatment of Inflammatory Bowel Disease.\u201d","volume-title":"European Journal of Hospital Pharmacy: Science and Practice","author":"Martin-Gutierrez","year":"2022"},{"key":"2024020222264962400_CIT0023","first-page":"172","article-title":"\u201cSafety and Clinical Efficacy of the Double Switch from Originator Infliximab to Biosimilars CT-P13 and SB2 in Patients with Inflammatory Bowel Diseases (SCESICS): A Multicenter Cohort Study.\u201d","volume-title":"Clinical and Translational Science","author":"Mazza","year":"2022"},{"key":"2024020222264962400_CIT0024","first-page":"97","article-title":"\u201cSwitching from IFX Originator to Biosimilar CT-P13 Does not Impact Effectiveness, Safety and Immunogenicity in a Large Cohort of IBD Patients.\u201d","volume-title":"Expert Opinion on Biological Therapy","author":"Pugliese","year":"2021"},{"key":"2024020222264962400_CIT0025","first-page":"700","article-title":"\u201cEfficacy and Tolerability of Initiating, or Switching to, Infliximab Biosimilar CT-P13 in Inflammatory Bowel Disease (IBD): a Large Single-Centre Experience.\u201d","volume-title":"Scandinavian Journal of Gastroenterology","author":"Ratnakumaran","year":"2018"},{"key":"2024020222264962400_CIT0026","first-page":"690","article-title":"\u201cBiosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme.\u201d","volume-title":"Journal of Crohn\u2019s & Colitis","author":"Razanskaite","year":"2017"},{"key":"2024020222264962400_CIT0027","first-page":"356","article-title":"\u201cSwitching from Infliximab Innovator to Biosimilar in Patients with Inflammatory Bowel Disease: A 12-Month Multicentre Observational Prospective Cohort Study.\u201d","volume-title":"Alimentary Pharmacology & Therapeutics","author":"Schmitz","year":"2018"},{"key":"2024020222264962400_CIT0028","first-page":"507","article-title":"\u201cSB5: An Adalimumab Biosimilar.\u201d","volume-title":"BioDrugs","author":"Frampton","year":"2018"},{"key":"2024020222264962400_CIT0029","first-page":"otab022","article-title":"\u201cThe Efficacy and Safety of Switching From Originator Infliximab to Single or Double Switch Biosimilar Among a Nationwide Cohort of Inflammatory Bowel Disease Patients.\u201d","volume-title":"Crohn\u2019s & Colitis 360","author":"Khan","year":"2021"},{"key":"2024020222264962400_CIT0030","first-page":"201","article-title":"\u201cSafety and Efficacy of Switching from Infliximab Biosimilar CT-P13 to Infliximab Biosimilar SB2 in Patients with Inflammatory Bowel Disease.\u201d","volume-title":"European Journal of Gastroenterology & Hepatology","author":"Lovero","year":"2021"},{"key":"2024020222264962400_CIT0031","first-page":"678","article-title":"\u201cAn Observational Study of Switching Infliximab Biosimilar: No Adverse Impact on Inflammatory Bowel Disease Control or Drug Levels with First or Second Switch.\u201d","volume-title":"Alimentary Pharmacology & Therapeutics","author":"Luber","year":"2021"},{"key":"2024020222264962400_CIT0032","first-page":"3041","article-title":"\u201cSPOSAB ABP 501: A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501.\u201d","volume-title":"Journal of Gastroenterology and Hepatology","author":"Macaluso","year":"2021"},{"key":"2024020222264962400_CIT0033","first-page":"17562848211023384","article-title":"\u201cSwitching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study.\u201d","volume-title":"Therapeutic Advances in Gastroenterology","author":"Massimi","year":"2021"},{"key":"2024020222264962400_CIT0034","first-page":"887","article-title":"\u201cOutcomes after Double Switching from Originator Infliximab to Biosimilar CT-P13 and Biosimilar SB2 in Patients with Inflammatory Bowel Disease: A 12-Month Prospective Cohort Study.\u201d","volume-title":"Alimentary Pharmacology & Therapeutics","author":"Trystram","year":"2021"},{"key":"2024020222264962400_CIT0035","first-page":"182","article-title":"\u201cThe SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches.\u201d","volume-title":"Inflammatory Bowel Diseases","author":"Macaluso","year":"2021"},{"key":"2024020222264962400_CIT0036","first-page":"10368","article-title":"\u201cAdalimumab Biosimilars, ABP501 and SB5, are Equally Effective and Safe as Adalimumab Originator.\u201d","volume-title":"Scientific Reports","author":"Cingolani","year":"2021"},{"key":"2024020222264962400_CIT0037","first-page":"195","article-title":"\u201cEffectiveness and Safety of Adalimumab Biosimilar ABP 501 in Crohn\u2019s Disease: An Observational Study.\u201d","volume-title":"Revista espanola de enfermedades digestivas: organo oficial de la Sociedad Espanola de Patologia Digestiva","author":"Ribaldone","year":"2020"},{"key":"2024020222264962400_CIT0038","first-page":"411","article-title":"\u201cReplacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy.\u201d","volume-title":"Journal of Gastrointestinal and Liver Diseases","author":"Tursi","year":"2022"},{"key":"2024020222264962400_CIT0039","first-page":"557","article-title":"\u201cEvaluation of the Safety and Effectiveness after Switch from Adalimumab Originator to Biosimilar SB5 in Patients with Inflammatory Bowel Disease in a Real-Life Setting.\u201d","volume-title":"Acta Gastro-enterologica Belgica","author":"Deprez","year":"2022"},{"key":"2024020222264962400_CIT0040","first-page":"814","article-title":"\u201cA Switch from Originator-Adalimumab to the Biosimilar SB5 in Patients with Crohn\u2019s Disease: An Analysis of Two Propensity Score-Matched Cohorts.\u201d","volume-title":"Scandinavian Journal of Gastroenterology","author":"Lukas","year":"2022"},{"key":"2024020222264962400_CIT0041","first-page":"915","article-title":"\u201cSwitching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre.\u201d","volume-title":"Journal of Crohn\u2019s & Colitis","author":"Lukas","year":"2020"},{"key":"2024020222264962400_CIT0042","first-page":"62","article-title":"\u201cEffectiveness and Safety of Nonmedical Switch From Adalimumab Originator to SB5 Biosimilar in Patients With Inflammatory Bowel Diseases: Twelve-Month Follow-Up From the TABLET Registry.\u201d","volume-title":"Inflammatory Bowel Diseases","author":"Tapete","year":"2022"},{"key":"2024020222264962400_CIT0043","first-page":"2011","article-title":"\u201cEffectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naive SB5 Observational Cohorts.\u201d","volume-title":"Journal of Crohn\u2019s & Colitis","author":"Derikx","year":"2021"},{"key":"2024020222264962400_CIT0044","first-page":"3387","article-title":"\u201cSwitching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn\u2019s Disease: A Prospective Study.\u201d","volume-title":"Journal of Clinical Medicine","author":"Ribaldone","year":"2021"},{"key":"2024020222264962400_CIT0045","first-page":"1639","article-title":"\u201cNon-Medical Switch from the Originator to Biosimilar and Between Biosimilars of Adalimumab in Inflammatory Bowel Disease - A Prospective, Multicentre Study.\u201d","volume-title":"Digestive and Liver Disease","author":"Lontai","year":"2022"},{"key":"2024020222264962400_CIT0046","first-page":"628","article-title":"\u201cEvaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center.\u201d","volume-title":"Inflammatory Bowel Diseases","author":"Bronswijk","year":"2020"},{"key":"2024020222264962400_CIT0047","first-page":"1348","article-title":"\u201cSwitching Maintenance Infliximab Therapy to Biosimilar Infliximab in Inflammatory Bowel Disease Patients.\u201d","volume-title":"Scandinavian Journal of Gastroenterology","author":"Eberl","year":"2017"},{"key":"2024020222264962400_CIT0048","first-page":"1756284820982802","article-title":"\u201cLong-Term Effectiveness, Safety and Immunogenicity of the Biosimilar SB2 in Inflammatory Bowel Disease Patients After Switching from Originator INFLIXIMAB.\u201d","volume-title":"Therapeutic Advances in Gastroenterology","author":"Fischer","year":"2021"},{"key":"2024020222264962400_CIT0049","first-page":"1660","article-title":"\u201cImplementation of CT-P13 via a Managed Switch Programme in Crohn\u2019s Disease: 12-Month Real-World Outcomes.\u201d","volume-title":"Digestive Diseases and Sciences","author":"Plevris","year":"2019"},{"key":"2024020222264962400_CIT0050","first-page":"1236","article-title":"\u201cAdalimumab Maintains Remission of Crohn\u2019s Disease After up to 4 Years of Treatment: Data from CHARM and ADHERE.\u201d","volume-title":"Alimentary Pharmacology and Therapeutics","author":"Panaccione","year":"2013"},{"key":"2024020222264962400_CIT0051","first-page":"1541","article-title":"\u201cMaintenance Infliximab for Crohn\u2019s Disease: The ACCENT I Randomised Trial.\u201d","volume-title":"Lancet","author":"Hanauer","year":"2002"},{"key":"2024020222264962400_CIT0052","first-page":"674","article-title":"\u201cLoss of Response and Need for Adalimumab Dose Intensification in Crohn\u2019s Disease: A Systematic Review.\u201d","volume-title":"American Journal of Gastroenterology","author":"Billioud","year":"2011"},{"key":"2024020222264962400_CIT0053","first-page":"987","article-title":"\u201cReview Article: Loss of Response to Anti-TNF Treatments in Crohn\u2019s Disease.\u201d","volume-title":"Alimentary Pharmacology and Therapeutics","author":"Ben-Horin","year":"2011"},{"key":"2024020222264962400_CIT0054","first-page":"667","article-title":"\u201cLimited Long-Term Treatment Persistence of First anti-TNF Therapy in 538 Patients with Inflammatory Bowel Diseases: A 20-Year Real-World Study.\u201d","volume-title":"Alimentary Pharmacology and Therapeutics","author":"Blesl","year":"2021"},{"key":"2024020222264962400_CIT0055","first-page":"5288","article-title":"\u201cLoss of Efficacy and Safety of the Switch from Infliximab Original to Infliximab Biosimilar (CT-P13) in Patients with Inflammatory Bowel Disease.\u201d","volume-title":"World Journal of Gastroenterology","author":"Guerra Veloz","year":"2018"},{"issue":"1","key":"2024020222264962400_CIT0056","first-page":"1","article-title":"\u201cSwitching from Infliximab to Biosimilar in Inflammatory Bowel Disease: A Review of Existing Literature and Best Practices.\u201d","volume":"3","author":"Bhat","year":"2021","journal-title":"Crohn\u2019s & Colitis 360"},{"key":"2024020222264962400_CIT0057","first-page":"2304","article-title":"\u201cSwitching from Originator Infliximab to Biosimilar CT-P13 Compared with Maintained Treatment with Originator Infliximab (NOR-SWITCH): A 52-Week, Randomised, Double-Blind, Non-Inferiority Trial.\u201d","volume-title":"Lancet","author":"Jorgensen","year":"2017"},{"key":"2024020222264962400_CIT0058","first-page":"203","article-title":"\u201cA Systematic Review on Infliximab Biosimilar SB2: From Pre-Clinical Data to Real-World Evidence.\u201d","volume-title":"Expert Opinion on Biological Therapy","author":"Macaluso","year":"2022"},{"key":"2024020222264962400_CIT0059","first-page":"CD013068","article-title":"\u201cEffectiveness and Safety of Switching IBD Patients from the Originator to the Biosimilar Infliximab.\u201d","volume-title":"Cochrane Database of Systematic Reviews (Online)","author":"Strik","year":"2018"},{"key":"2024020222264962400_CIT0060","first-page":"2354","article-title":"\u201cSystematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease.\u201d","volume-title":"Digestive Diseases and Sciences","author":"Bernard","year":"2020"},{"key":"2024020222264962400_CIT0061","first-page":"31","article-title":"\u201cSystematic Review: Efficacy and Safety of Switching Patients Between Reference and Biosimilar Infliximab.\u201d","volume-title":"Alimentary Pharmacology & Therapeutics","author":"Feagan","year":"2019"},{"key":"2024020222264962400_CIT0062","first-page":"358","article-title":"\u201cInfliximab Switching from Reference Product to Biosimilar: A Review of Evidence Regarding the Clinical Efficacy, Safety Profile and Immunogenicity.\u201d","volume-title":"Journal of Pharmacy Practice and Research","author":"Abidin","year":"2021"},{"key":"2024020222264962400_CIT0063","first-page":"241","article-title":"\u201cAdalimumab Biosimilars in Europe: An Overview of the Clinical Evidence.\u201d","volume-title":"BioDrugs","author":"Bellinvia","year":"2019"},{"key":"2024020222264962400_CIT0064","first-page":"565","article-title":"\u201cBioequivalence of Biosimilar Tumor Necrosis Factor-\u03b1 Inhibitors Compared With Their Reference Biologics: A Systematic Review.\u201d","volume-title":"Annals of Internal Medicine","author":"Chingcuanco","year":"2016"},{"key":"2024020222264962400_CIT0065","first-page":"625","article-title":"\u201cSwitching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies.\u201d","volume-title":"BioDrugs","author":"Cohen","year":"2022"},{"key":"2024020222264962400_CIT0066","first-page":"1633","article-title":"\u201cAn Updated Systematic Review and Meta-Analysis About the Safety and Efficacy of Infliximab Biosimilar, CT-P13, for Patients with Inflammatory Bowel Disease.\u201d","volume-title":"International Journal of Colorectal Disease","author":"Ebada","year":"2019"},{"key":"2024020222264962400_CIT0067","first-page":"1043","article-title":"\u201cSystematic Review with Meta-Analysis: the Efficacy and Safety of CT-P13, a Biosimilar of Anti-Tumour Necrosis Factor-Alpha Agent (Infliximab), in Inflammatory Bowel Diseases.\u201d","volume-title":"Alimentary Pharmacology & Therapeutics","author":"Komaki","year":"2017"},{"key":"2024020222264962400_CIT0068","first-page":"37","article-title":"\u201cInfliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review.\u201d","volume-title":"BioDrugs","author":"Radin","year":"2017"},{"key":"2024020222264962400_CIT0069","first-page":"109","article-title":"\u201cCurrent Evidence on the Use of the Adalimumab Biosimilar SB5 (ImraldiTM): A Multidisciplinary Perspective.\u201d","volume-title":"Expert Opinion on Biological Therapy","author":"Gisbert","year":"2022"},{"key":"2024020222264962400_CIT0070","first-page":"309","article-title":"\u201cReal-World Patient Experience of Switching Biologic Treatment in Inflammatory Arthritis and Ulcerative Colitis - A Systematic Literature Review.\u201d","volume-title":"Patient Prefer Adherence","author":"Luttropp","year":"2020"},{"key":"2024020222264962400_CIT0071","first-page":"917814","article-title":"\u201cSwitching Among Biosimilars: A Review of Clinical Evidence.\u201d","volume-title":"Frontiers in Pharmacology","author":"Allocati","year":"2022"},{"key":"2024020222264962400_CIT0072","first-page":"408","article-title":"\u201cAnti-TNF and Immunosuppressive Combination Therapy is Preferential to Inducing Clinical Remission in Patients with Active Inflammatory Bowel Disease: A Systemic Review and Meta-Analysis.\u201d","volume-title":"Journal of Digestive Diseases","author":"Chen","year":"2021"},{"key":"2024020222264962400_CIT0073","first-page":"389","article-title":"\u201cSwitching from an Originator anti-TNF to a Biosimilar in Patients with Inflammatory Bowel disease: Can it be Recommended? A Systematic Review.\u201d","volume-title":"Gastroenterologia y Hepatologia","author":"Gisbert","year":"2018"},{"key":"2024020222264962400_CIT0074","first-page":"otab015","article-title":"\u201cThe Great Debate With IBD Biosimilars: Pro: Biosimilars Should Be Routinely Used as a First Line Biologic and May Be Switched From Reference Biologics.\u201d","volume-title":"Crohns Colitis 360","author":"Limdi","year":"2021"},{"key":"2024020222264962400_CIT0075","volume-title":"Summary: Patient and Health Care Provider Input \u2013 Non-Medical Biosimilar Switch Policy for Patients with Inflammatory Bowel Disease","author":"Crohn\u2019s and Colitis Canada","year":"2019"},{"key":"2024020222264962400_CIT0076","first-page":"394","article-title":"\u201cThe Addition of an Immunosuppressant After Loss of Response to Anti-TNF\u03b1 Monotherapy in Inflammatory Bowel Disease: A 2-Year Study.\u201d","volume-title":"Inflammatory Bowel Diseases","author":"Macaluso","year":"2018"},{"key":"2024020222264962400_CIT0077","first-page":"234","article-title":"\u201cThe Argument Against a Biosimilar Switch Policy for Infliximab in Patients with Inflammatory Bowel Disease Living in Alberta.\u201d","volume-title":"Journal of the Canadian Association of Gastroenterology","author":"Kaplan","year":"2020"},{"key":"2024020222264962400_CIT0078","first-page":"26","article-title":"\u201cECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update.\u201d","volume-title":"Journal of Crohn\u2019s & Colitis","author":"Danese","year":"2017"},{"key":"2024020222264962400_CIT0079","first-page":"e1","article-title":"\u201cJoint Canadian Association of Gastroenterology and Crohn\u2019s Colitis Canada Position Statement on Biosimilars for the Treatment of Inflammatory Bowel Disease.\u201d","volume-title":"Journal of the Canadian Association of Gastroenterology","author":"Moayyedi","year":"2020"},{"key":"2024020222264962400_CIT0080","first-page":"A456","article-title":"\u201cSwitch of Infliximab Originator to Biosimilar CT-P13 in Patients with Crohn\u2019s Disease and Ulcerative Colitis in a Large German IBD Center. A One Year, Randomized and Prospective Trial.\u201d","volume":"6","author":"Roder","year":"2018","journal-title":"United European Gastroenterology Journal"},{"key":"2024020222264962400_CIT0081","first-page":"607","article-title":"\u201cLong-term Outcomes After Switching to CT-P13 in Pediatric-Onset Inflammatory Bowel Disease: A Single-Center Prospective Observational Study.\u201d","volume-title":"Inflammatory Bowel Diseases","author":"Kang","year":"2018"},{"key":"2024020222264962400_CIT0082","first-page":"653","article-title":"\u201cLong-Term Efficacy and Safety of Biosimilar Infliximab (CT-P13) After Switching from Originator Infliximab: Open-Label Extension of the NOR-SWITCH Trial.\u201d","volume-title":"Journal of Internal Medicine","author":"Goll","year":"2019"},{"key":"2024020222264962400_CIT0083","first-page":"1699","article-title":"\u201cEfficacy and Safety of Biosimilar CT-P13 Compared with Originator Infliximab in Patients with Active Crohn\u2019s Disease: An International, Randomised, Double-Blind, Phase 3 Non-Inferiority Study.\u201d","volume-title":"Lancet","author":"Ye","year":"2019"},{"key":"2024020222264962400_CIT0084","first-page":"816","article-title":"\u201cSafety and Efficacy of BI 695501 Versus Adalimumab Reference Product in Patients with Advanced Crohn\u2019s Disease (VOLTAIRE-CD): A Multicentre, randomised, Double-Blind, Phase 3 Trial.\u201d","volume-title":"The Lancet Gastroenterology & Hepatology","author":"Hanauer","year":"2021"},{"key":"2024020222264962400_CIT0085","first-page":"681","article-title":"\u201cEfficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials.\u201d","volume-title":"BioDrugs","author":"Jorgensen","year":"2020"},{"key":"2024020222264962400_CIT0086","first-page":"1705","article-title":"\u201cEfficacy and Safety of CT-P13, a Biosimilar of Infliximab, in Patients with Inflammatory Bowel Disease: A Retrospective Multicenter Study.\u201d","volume-title":"Journal of Gastroenterology and Hepatology","author":"Jung","year":"2015"},{"key":"2024020222264962400_CIT0087","first-page":"1019","article-title":"\u201cBiosimilar Switching in Inflammatory Bowel Disease: From Evidence to Clinical Practice.\u201d","volume-title":"Expert Review of Clinical Immunology","author":"Solitano","year":"2020"},{"key":"2024020222264962400_CIT0088","volume-title":"NON-MEDICAL SWITCH PATIENT DECISION MATRIX","author":"Crohn\u2019s and Colitis Canada","year":"2023"},{"key":"2024020222264962400_CIT0089","first-page":"312","article-title":"\u201cHow Achievable are STRIDE-II Treatment Targets in Real-World Practice and do They Predict Long-Term Treatment Outcomes?.\u201d","volume-title":"Frontline Gastroenterology","author":"Meade","year":"2022"},{"key":"2024020222264962400_CIT0090","first-page":"1","article-title":"\u201cA Propensity Score-Weighted Comparison Between Adalimumab Originator and its Biosimilars, ABP501 and SB5, in Inflammatory Bowel Disease: A Multicenter Italian Study.\u201d","volume-title":"Therapeutic Advances in Gastroenterology","author":"Barberio","year":"2021"},{"key":"2024020222264962400_CIT0091","first-page":"161","article-title":"\u201cEfficacy and Safety of Biologics and Small Molecule Drugs for Patients with Moderate-to-Severe Ulcerative Colitis: A Systematic Review and Network Meta-Analysis.\u201d","volume-title":"Lancet Gastroenterology and Hepatology","author":"Lasa","year":"2022"},{"key":"2024020222264962400_CIT0092","first-page":"2506","article-title":"\u201cOutcomes of Patients With Inflammatory Bowel Diseases Switched From Maintenance Therapy With a Biosimilar to Remicade.\u201d","volume-title":"Clinical Gastroenterology and Hepatology","author":"Ilias","year":"2019"},{"key":"2024020222264962400_CIT0093","first-page":"1954","article-title":"\u201cOutcome of Reverse Switching From CT-P13 to Originator Infliximab in Patients With Inflammatory Bowel Disease.\u201d","volume-title":"Inflammatory Bowel Diseases","author":"Mahmmod","year":"2021"},{"key":"2024020222264962400_CIT0094","first-page":"639","article-title":"\u201cThe Nocebo Effect in a Non-Medical Switching Program from Originator to Biosimilar Infliximab in Inflammatory Bowel Disease.\u201d","volume-title":"BioDrugs","author":"Dutt","year":"2022"}],"container-title":["Journal of the Canadian Association of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcag\/article-pdf\/7\/1\/30\/56554388\/gwad027.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcag\/article-pdf\/7\/1\/30\/56554388\/gwad027.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T22:27:24Z","timestamp":1706912844000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcag\/article\/7\/1\/30\/7329707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,25]]},"references-count":94,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,10,25]]},"published-print":{"date-parts":[[2024,2,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jcag\/gwad027","relation":{},"ISSN":["2515-2084","2515-2092"],"issn-type":[{"value":"2515-2084","type":"print"},{"value":"2515-2092","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2,1]]},"published":{"date-parts":[[2023,10,25]]}}}